SCHEMBL14814588

SCHEMBL14814588

O=C(c1ccc(F)cc1)N1CCN2C[C@@H](NS(=O)(=O)c3cccc(C(F)(F)F)c3)C[C@H]2C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.47
▸ HSD11B1 P28845 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ CASP7 P55210 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ UBE2M P61081 1/20 0.46
▸ DCUN1D1 Q96GG9 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.45
▸ HDAC8 Q9BY41 1/20 0.45
▸ CCR2 P41597 1/20 0.44
▸ DRD2 P14416 1/20 0.44
▸ ADRA1D P25100 1/20 0.44
▸ ADRA1A P35348 1/20 0.44
▸ ADRA1B P35368 1/20 0.44
▸ PKLR P30613 1/20 0.44
▸ CACNA1H O95180 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14833243 1.00 ALDH1A1 (0.47) ALDH1A1HSD11B1SMN1; SMN2HPGDCASP1
SCHEMBL14833432 0.95 ALDH1A1 (0.49) ALDH1A1HSD11B1SMN1; SMN2HPGDCASP1
SCHEMBL14815172 0.95 ALDH1A1 (0.49) ALDH1A1HSD11B1SMN1; SMN2HPGDCASP1
SCHEMBL14815367 0.87 DRD2 (0.46) ALDH1A1HSD11B1SMN1; SMN2HPGDCASP1
SCHEMBL14833216 0.84 CCR2 (0.54) HSD11B1SMN1; SMN2HPGDUBE2MDCUN1D1
SCHEMBL14815069 0.84 CCR2 (0.54) HSD11B1SMN1; SMN2HPGDUBE2MDCUN1D1
SCHEMBL14833207 0.83 HSD11B1 (0.53) HSD11B1SMN1; SMN2HPGDUBE2MDCUN1D1
SCHEMBL14815282 0.83 HSD11B1 (0.53) HSD11B1SMN1; SMN2HPGDUBE2MDCUN1D1
SCHEMBL14815270 0.78 L3MBTL3 (0.56) HSD11B1HPGDCCR2
SCHEMBL14833250 0.78 L3MBTL3 (0.56) HSD11B1HPGDCCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669255-B2 Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers ABBVIE INC. (US) 2014-03-11 — — US claimed
US-8669255-B2 Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers ABBVIE INC. (US) 2014-03-11 — — US disclosed
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, CACNA1E, CACNA1D ALDH1A1 1283/4885HSD11B1 2566/4885SMN1; SMN2 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback